European Medicines Agency (EMA)
who
Clinical Trials Information System (CTIS) designated as WHO primary registry

Designation facilitates data sharing, promotes transparency and trust in clinical research

Read news on designation
Magnified biosimilar medicine
Streamlining development and assessment of biosimilar medicines

Public consultation open until end September 2025

Send your comments
Cows and a veterinary
First report on EU-wide sales and use of antimicrobials in animals

Data collection is key in tackling antimicrobial resistance

Read the report
CHMP slider
Human medicines committee meeting: March 2025 highlights

CHMP recommends five new medicines for approval in the EU

Read highlights
Network strategy to 2028
EU medicines agencies’ network strategy to 2028

Seizing opportunities in a changing medicines landscape

Read strategy
Cell therapy
Authorities warn against risks of unregulated Advanced Therapies Medicinal Products (ATMPs)

Patients invited to report suspicious offers

Learn more about unregulated ATMPs
Icon Magnify Glass

Find medicine

Find information on centrally authorised medicines
Icon Megaphone

What's new

Find all new and updated information published on our website in one place
icon speech question answer

FAQs

Find answers to the most frequent asked questions we receive

Latest news

SEE ALL NEWS

Events

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system

EudraVigilance is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of...

Online
Start date: 31 March 2025
End date: 4 April 2025
SEE ALL EVENTS
EMA Custom Webtools Rating widget: Hidden by field_ema_hide_rating for this node.
Back to top